BioLife Solutions Partners with Qkine to Enhance Cytokine Offerings in the Gene Therapy Sector

BioLife Solutions Partners with Qkine Limited

In a significant move to strengthen its product offerings, BioLife Solutions, Inc. (NASDAQ: BLFS), a prominent player in the biotechnology industry, has announced a multi-year supply agreement with Qkine Limited, a recognized innovator in the field of cytokines. This collaboration marks a crucial step for BioLife as it aims to expand into the rapidly growing market for cytokines, which are essential components in cell and gene therapy (CGT).

Details of the Agreement

Under this newly established agreement, BioLife will take on the role of exclusive worldwide distributor for select Qkine products tailored specifically for the CGT market. Additionally, the company will also hold non-exclusive distribution rights for other Qkine products within the same sector. This partnership is not merely a transaction; it is designed to foster collaboration between the two companies to enhance the development and validation processes for a range of cytokine and growth factor products.

One of the key aspects of this collaboration is the joint effort to incorporate Qkine’s products into BioLife's proprietary CellSeal® Connect vial system. This innovative system is intended for use in closed and automated CGT workflows, a critical advancement that aligns with current trends towards increased efficiency and versatility in the bioproduction process.

BioLife's Chairman and CEO, Roderick de Greef, expressed enthusiasm for the partnership, highlighting the synergy between the two companies. He stated, “We are pleased to establish this strategic distribution and CellSeal® Connect product development relationship with Qkine, a recognized leader in the fast-growing cytokines market.” He emphasized that Qkine's cytokine products complement BioLife’s existing cell culture supplements, thereby enriching the company's product portfolio for CGT customers and aligning with BioLife's long-term growth strategy.

The Importance of Cytokines in Gene Therapy

Cytokines and growth factors play a pivotal role in the sphere of cell and gene therapies, regulating various cellular processes such as growth, activation, and performance. This partnership comes at a time when the global cytokines market is witnessing explosive growth. Recent studies estimate the market size at approximately $500 million annually, with projections indicating robust growth to reach $1 billion by 2030, influenced by the expanding pipelines for CGT development.

Dr. Robert Scoffin, Qkine’s CEO, shared his excitement about the new partnership, stating, “This collaboration brings together our expertise in cytokine innovation with BioLife’s extensive reach and customer relationships in the CGT market.” He reiterated the shared goal of delivering enhanced value to customers while advancing the development and manufacturing processes of next-generation therapies.

Future Prospects

Looking ahead, this strategic alliance between BioLife Solutions and Qkine Limited is set to reinforce the foundation for developing cutting-edge therapies in regenerative medicine. By combining their expertise and resources, they aim to create robust solutions that cater to the unique demands of the CGT marketplace.

BioLife Solutions, based in Bothell, Washington, has made its mark as a leading developer and supplier of bioproduction products and services, critical for the cell and gene therapy sectors. Their commitment to ensuring the health and efficacy of biologic materials throughout the entire production process underlines their dedication to the advancement of therapeutic innovations.

In conclusion, the collaboration between these two industry leaders showcases a proactive approach to addressing the evolving needs of the biotechnology field and positions them well for the opportunities that lie ahead in the cytokines market.

For more information about BioLife Solutions and their offerings, visit BioLife Solutions or follow them on LinkedIn and Twitter.